Physician profile
Current Custer Patterson
NPI 1407070824
$4,706.25
in general payments reported to CMS, 2019-2025
21 companies · $898 in 2025
The $898 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $276 · 2021: $587 · 2022: $720 · 2023: $886 · 2024: $916 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298 · Education: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.00 |
| Education | $402.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,026.15 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Janssen Biotech, INC. | $919.62 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $671.43 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Pfizer INC. | $269.80 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $264.83 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $225.42 | 2019-2025 | Dupixent |
| Ucb, INC. | $206.64 | 2022-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $196.71 | 2020-2025 | |
| Lilly USA, LLC | $194.26 | 2019-2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $131.14 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $115.55 | 2023-2024 | Vtama |
| Genentech USA, INC. | $109.49 | 2019-2023 | Erivedge |
| Biofrontera INC. | $92.09 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $74.14 | 2019-2025 | Dysport, Nemluvio |
| Merz North America, INC. | $46.12 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $41.01 | 2019-2022 | |
| Allergan, INC. | $36.56 | 2019-2022 | |
| Organon LLC | $23.29 | 2025 | |
| Incyte Corporation | $21.88 | 2022 | |
| Amgen INC. | $20.51 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $19.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Current Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.